Board of directors
|
|
Kerstin Valinder Strinnholm Executive Chairman Born 1960. Active in the company since 2022. Kerstin holds a degree in Journalism från the University of Gothenburg, Sweden. Kerstin brings more than 30 years of international pharma experience. She has worked in leading positions at e.g. AstraZeneca and Nycomed/Takeda, with a primary focus on commercial and business strategic areas. Currently Kerstin acts as business advisor at transactions within the life science fied and is also non-executive member of the boards of Camurus AB and Immedica AB. Shareholding: 39 632 shares. Independent in relation to the company and the owners. |
|
|
Jonas Ekblom
Born 1965. Active in the company since 2024. Jonas has a bachelor's degree in chemistry from Stockholm University, a doctorate in medical sciences from Uppsala University and a postdoctoral education from the University of Southern California in Los Angeles, USA. Since 1996, Jonas holds an associate professorship in pharmacology at Uppsala University. Jonas has worked for three decades in research and development of pharmaceutical and medtech products. Jonas has held board and management positions in public and privately held life science companies in Sweden, Switzerland and the USA. He has served as CEO of BOWS Pharmaceuticals SA, Pergamum AB and Promore Pharma AB. Today, Jonas is chairman of the board in Oblique Therapeutics AB (publ.) and partner in Ekblom & Denissenko. Shareholding: 0 shares. Independent in relation to the company and the owners. |
|
|
Håkan Wallin Born 1962. Member since 2023. Håkan has many years of both operative and financial experience from advisory positions as well as from board- and management positions in both listed and non-listed life science companies. Previous positions include responsible partner for the life science sector within corporate finance at ABG Sundal Collier, Head of Business Development at Medivir and Chairman of the Board of Directors in Palette Life Sciences (previously Pharmanest AB) and auditor at Arthur Andersen. Håkan has experience from several other sectors and is today CFO at NP3 Fastigheter AB (publ.). Håkan is Board member of Cibola Hospitality Group AB, Östersjöstifltelsens Placeringsdelegation and HWA Advisory & Capital AB. Shareholding: 0 shares. Independent in relation to the company. |
 |
Nikolaj Sørensen Born 1972. Board members since 2021. Nikolaj Sörensen has more than 20 years of experience from the life science and the pharmaceutical industry in Sweden and abroad. Nikolaj today serves as President and CEO of Orexo AB. Previous appointments includes senior management positions at Pfizer and as management consultant at the Boston Consulting Group (BCG). Nikolaj has a M.Sc. in International Business from Copenhagen Business School. Nikolaj is Board member of Gesynta Pharma AB. Shareholding: 28 902 shares. independent from the company and the owners. |
Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.